Inflammatory bowel disease: Past, present, and future

Journal of Gastroenterology

Volumn 42, Issue 1, 2007, Pages 16-25

  Sands, Bruce E ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Crohn's disease; Inflammatory bowel diseases; Medical therapy; Pathogenesis; Ulcerative colitis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB; CORTICOSTEROID; CYCLOSPORIN; DACLIZUMAB; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROCORTISONE; INTERLEUKIN 10; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; MLN 02; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CA2; NATALIZUMAB; NONSTEROID ANTIINFLAMMATORY AGENT; ORNIDAZOLE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG; VISILIZUMAB;

CLINICAL TRIAL; CROHN DISEASE; ENTERITIS; GENETIC SUSCEPTIBILITY; HOST SUSCEPTIBILITY; HUMAN; IMMUNE RESPONSE; INDUSTRIALIZATION; INFLAMMATION; INTESTINE FLORA; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; ULCERATIVE COLITIS; WESTERN HEMISPHERE;

ANIMALS; ANTI-BACTERIAL AGENTS; COLITIS, ULCERATIVE; CROHN DISEASE; GENETIC PREDISPOSITION TO DISEASE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE ACTIVATION; NOD2 SIGNALING ADAPTOR PROTEIN; POLYMORPHISM, GENETIC; RISK FACTORS; SMOKING;

EID: 33847632044     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-006-1995-7     Document Type: Review

References (101)

1. JB Kirsner 2001 Historical origins of current IBD concepts World J Gastroenterol 7 175-84 11819757 1:STN:280:DC%2BD383gs1GrtQ%3D%3D
2. BB Crohn L Ginzburg GD Oppenheimer 2000 Regional ileitis: A pathologic and clinical entity. 1932 Mt Sinai J Med 67 263-8 10828911 1:STN:280:DC%2BD3c3ptFGlsw%3D%3D
3. HE Lockhart-Mummery BC Morson 1960 Crohn's disease (regional enteritis) of the large intestine and its distinction from ulcerative colitis Gut 1 87-105 14417801 1:STN:280:CC%2BC2s%2FkslM%3D
4. AK Azad Khan J Piris SC Truelove 1977 An experiment to determine the active therapeutic moiety of sulphasalazine Lancet 2 892-5 72239 10.1016/ S0140-6736(77)90831-5 1:STN:280:CSeD3s%2FkslI%3D
5. MA Peppercorn P Goldman 1972 The role of intestinal bacteria in the metabolism of salicylazosulfapyridine J Pharmacol Exp Ther 181 555-62 4402374 1:CAS:528:DyaE38Xks12qt7c%3D
6. HP Kaplan B Portnoy HJ Binder T Amatruda H Spiro 1975 A controlled evaluation of intravenous adrenocorticotropic hormone and hydrocortisone in the treatment of acute colitis Gastroenterology 69 91-5 168121 1:STN:280:CSqB3cbotVI%3D
7. SC Truelove DP Jewell 1974 Intensive intravenous regimen for severe attacks of ulcerative colitis Lancet 1 1067-70 4135487 10.1016/ S0140-6736(74)90552-2 1:STN:280:CSuB2snotlM%3D
8. SC Truelove LJ Witts 1955 Cortisone in ulcerative colitis; final report on a therapeutic trial BMJ 4947 1041-8
9. P Munkholm E Langholz M Davidsen V Binder 1994 Frequency of glucocorticoid resistance and dependency in Crohn's disease Gut 35 360-2 8150347 1:STN:280:ByuB3c%2Fms1c%3D
10. DH Present BI Korelitz N Wisch JL Glass DB Sachar BS Pasternack 1980 Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study N Engl J Med 302 981-7 6102739 1:STN:280:Bi%2BC28rjs1U%3D
11. BI Korelitz DH Present 1985 Favorable effect of 6-mercaptopurine on fistulae of Crohn's disease Dig Dis Sci 30 58-64 2856904 10.1007/ BF01318372 1:STN:280:BiqD2snhtlM%3D
12. S Ardizzone G Maconi A Russo V Imbesi E Colombo G Bianchi Porro 2006 Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis Gut 55 47-53 15972298 10.1136/gut.2005.068809 1:STN:280:DC%2BD2Mnmt1SrtQ%3D%3D
13. BG Feagan J Rochon RN Fedorak EJ Irvine G Wild L Sutherland 1995 Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators N Engl J Med 332 292-7 7816064 10.1056/ NEJM199502023320503 1:STN:280:ByqC3MrntFI%3D
14. BG Feagan RN Fedorak EJ Irvine G Wild L Sutherland AH Steinhart 2000 A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators N Engl J Med 342 1627-32 10833208 10.1056/NEJM200006013422202 1:CAS:528:DC%2BD3cXktF2gsr4%3D
15. S Lichtiger DH Present A Kornbluth I Gelernt J Bauer G Galler 1994 Cyclosporine in severe ulcerative colitis refractory to steroid therapy N Engl J Med 330 1841-5 8196726 10.1056/NEJM199406303302601 1:STN:280:ByuB2Mvps1I%3D
16. J Arts G D'Haens M Zeegers G Van Assche M Hiele A D'Hoore 2004 Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis Inflamm Bowel Dis 10 73-8 15168804 10.1097/ 00054725-200403000-00002
17. VW Fazio F Marchetti M Church JR Goldblum C Lavery TL Hull 1996 Effect of resection margins on the recurrence of Crohn's disease in the small bowel. A randomized controlled trial Ann Surg 224 563-71 8857860 10.1097/ 00000658-199610000-00014 1:STN:280:ByiD3M%2Fot1M%3D discussion 571-3
18. AA Deutsch HS Stern 1989 Stapler stricturoplasty for Crohn's disease Surg Gynecol Obstet 169 458-60 2814760 1:STN:280:By%2BD2cbmsVA%3D
19. BM Taylor RW Beart Jr RR Dozois KA Kelly SF Phillips 1983 Straight ileoanal anastomosis v ileal pouch-anal anastomosis after colectomy and mucosal proctectomy Arch Surg 118 696-701 6847364 1:STN:280:BiyB3czjvFQ%3D
20. H Yang C McElree MP Roth F Shanahan SR Targan JI Rotter 1993 Familial empirical risks for inflammatory bowel disease: Differences between Jews and non-Jews Gut 34 517-24 8491401 1:STN:280:ByyB2MbkvFc%3D
21. C Tysk E Lindberg G Jarnerot B Floderus-Myrhed 1988 Ulcerative colitis and Crohn's disease in an unselected population of monozygotic and dizygotic twins. A study of heritability and the influence of smoking Gut 29 990-6 3396969 1:STN:280:BieB1cvltFE%3D
22. DK Podolsky 2002 Inflammatory bowel disease N Engl J Med 347 417-29 12167685 10.1056/NEJMra020831 1:CAS:528:DC%2BD38XlvFKrt7s%3D
23. J Hermon-Taylor T Bull 2002 Crohn's disease caused by Mycobacterium avium subspecies paratuberculosis: A public health tragedy whose resolution is long overdue J Med Microbiol 51 3-6 11800469
24. HS Odes A Fich S Reif A Halak A Lavy D Keter 2001 Effects of current cigarette smoking on clinical course of Crohn's disease and ulcerative colitis Dig Dis Sci 46 1717-21 11508673 10.1023/A:1010609722315 1:STN:280:DC%2BD3MvmsVahtA%3D%3D
25. I Bjarnason G Zanelli T Smith P Prouse P Williams P Smethurst 1987 Nonsteroidal antiinflammatory drug-induced intestinal inflammation in humans Gastroenterology 93 480-9 3609658 1:STN:280:BiiB2sjitlU%3D
26. M Frisch C Johansen L Mellemkjaer EA Engels G Gridley RJ Biggar 2001 Appendectomy and subsequent risk of inflammatory bowel diseases Surgery 130 36-43 11436010 10.1067/msy.2001.115362 1:STN:280:DC%2BD3Mvgs1yqtQ%3D%3D
27. J Cosnes L Beaugerie F Carbonnel JP Gendre 2001 Smoking cessation and the course of Crohn's disease: An intervention study Gastroenterology 120 1093-9 11266373 10.1053/gast.2001.23231 1:STN:280:DC%2BD3M7mvFOqtQ%3D%3D
28. EJ Boyko DR Perera TD Koepsell EM Keane TS Inui 1988 Effects of cigarette smoking on the clinical course of ulcerative colitis Scand J Gastroenterol 23 1147-52 3247593 1:STN:280:BiaB2c7psVI%3D
29. AD Harries A Baird J Rhodes 1982 Non-smoking: A feature of ulcerative colitis BMJ Clin Res Ed 284 7061:STN:280:Bi2C287ntlw%3D
30. RJ Motley J Rhodes GA Ford SP Wilkinson IM Chesner P Asquith 1987 Time relationships between cessation of smoking and onset of ulcerative colitis Digestion 37 125-7 3622939 1:STN:280:BiiA3critVw%3D
31. McGrath J, McDonald JW, Macdonald JK. Transdermal nicotine for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews 2004 Oct 18;(4):CD004722
32. RA Hegazi KN Rao A Mayle AR Sepulveda LE Otterbein SE Plevy 2005 Carbon monoxide ameliorates chronic murine colitis through a heme oxygenase 1-dependent pathway J Exp Med 202 1703-13 16365149 10.1084/jem.20051047 1:CAS:528:DC%2BD2MXhtlCjsrjL
33. C Dejaco M Harrer T Waldhoer W Miehsler H Vogelsang W Reinisch 2003 Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn's disease Aliment Pharmacol Ther 18 1113-20 14653831 10.1046/ j.1365-2036.2003.01793.x 1:CAS:528:DC%2BD2cXmt1SgtA%3D%3D
34. GE Wild 2004 The role of antibiotics in the management of Crohn's disease Inflamm Bowel Dis 10 321-3 15290930 10.1097/ 00054725-200405000-00022
35. P Rutgeerts M Hiele K Geboes M Peeters F Penninckx R Aerts 1995 Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection Gastroenterology 108 1617-21 7768364 10.1016/0016-5085(95)90121-3 1:STN:280:ByqB1crpslA%3D
36. P Rutgeerts G Van Assche S Vermeire G D'Haens F Baert M Noman 2005 Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial Gastroenterology 128 856-61 15825069 10.1053/j.gastro.2005.01.010 1:CAS:528:DC%2BD2MXjvV2qtrk%3D
37. P Rutgeerts K Goboes M Peeters M Hiele F Penninckx R Aerts 1991 Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum Lancet 338 771-4 1681159 10.1016/0140-6736(91)90663-A 1:STN:280:By2D3Mnns1U%3D
38. T Yamamoto M Nakahigashi S Umegae T Kitagawa K Matsumoto 2005 Impact of elemental diet on mucosal inflammation in patients with active Crohn's disease: Cytokine production and endoscopic and histological findings Inflamm Bowel Dis 11 580-8 15905706 10.1097/01.MIB.0000161307.58327.96
39. P Gionchetti F Rizzello U Helwig A Venturi KM Lammers P Brigidi 2003 Prophylaxis of pouchitis onset with probiotic therapy: A double-blind, placebo-controlled trial [see comment Gastroenterology 124 1202-9 12730861 10.1016/S0016-5085(03)00171-9
40. P Gionchetti F Rizzello A Venturi P Brigidi D Matteuzzi G Bazzocchi 2000 Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: A double-blind, placebo-controlled trial Gastroenterology 119 305-9 10930365 10.1053/gast.2000.9370 1:STN:280:DC%2BD3cvgtl2ltw%3D%3D
41. RN Fedorak KL Madsen 2004 Probiotics and the management of inflammatory bowel disease Inflamm Bowel Dis 10 286-99 15290926 10.1097/ 00054725-200405000-00018
42. KP Rioux RN Fedorak 2006 Probiotics in the treatment of inflammatory bowel disease J Clin Gastroenterol 40 260-3 16633133 10.1097/ 00004836-200603000-00019
43. R Duchmann E Schmitt P Knolle KH Meyer zum Buschenfelde M Neurath 1996 Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12 Eur J Immunol 26 934-8 8625991 1:CAS:528:DyaK28XisVKlurY%3D
44. A Stadnicki RW Colman 2003 Experimental models of inflammatory bowel disease Arch Immunol Ther Exp 51 149-55
45. ID Arnott CJ Landers EJ Nimmo HE Drummond BK Smith SR Targan 2004 Sero-reactivity to microbial components in Crohn's disease is associated with disease severity and progression, but not NOD2/CARD15 genotype Am J Gastroenterol 99 2376-84 15571586 10.1111/j.1572-0241.2004.40417.x
46. CJ Landers O Cohavy R Misra H Yang YC Lin J Braun 2002 Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbial antigens Gastroenterology 123 689-99 12198693 10.1053/gast.2002.35379 1:CAS:528:DC%2BD38Xntl2mtbk%3D
47. MJ Lodes Y Cong CO Elson R Mohamath CJ Landers SR Targan 2004 Bacterial flagellin is a dominant antigen in Crohn disease J Clin Invest 113 1296-306 15124021 10.1172/JCI200420295 1:CAS:528:DC%2BD2cXjvVOqs78%3D
48. WS Mow EA Vasiliauskas YC Lin PR Fleshner KA Papadakis KD Taylor 2004 Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease Gastroenterology 126 414-24 14762777 10.1053/j.gastro.2003.11.015 1:CAS:528:DC%2BD2cXhvV2rsbg%3D
49. LA Dieleman MS Goerres A Arends D Sprengers C Torrice F Hoentjen 2003 Lactobacillus GG prevents recurrence of colitis in HLA-B27 transgenic rats after antibiotic treatment Gut 52 370-6 12584218 10.1136/ gut.52.3.370 1:STN:280:DC%2BD3s%2FntlCgtg%3D%3D
50. SC Kim SL Tonkonogy CA Albright J Tsang EJ Balish J Braun 2005 Variable phenotypes of enterocolitis in interleukin 10-deficient mice monoassociated with two different commensal bacteria Gastroenterology 128 891-906 15825073 10.1053/j.gastro.2005.02.009 1:CAS:528:DC%2BD2MXjvV2qt78%3D
51. T Ahmad J Satsangi D McGovern M Bunce DP Jewell 2001 Review article: The genetics of inflammatory bowel disease Aliment Pharmacol Ther 15 731-48 11380312 10.1046/j.1365-2036.2001.00981.x 1:CAS:528:DC%2BD3MXks1Kisbg%3D
52. J Hampe A Cuthbert PJ Croucher MM Mirza S Mascheretti S Fisher 2001 Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations Lancet 357 1925-8 11425413 10.1016/ S0140-6736(00)05063-7 1:CAS:528:DC%2BD3MXks1OisLk%3D
53. JP Hugot M Chamaillard H Zouali S Lesage JP Cezard J Belaiche 2001 Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease Nature 411 599-603 11385576 10.1038/35079107 1:CAS:528:DC%2BD3MXksVShtLY%3D
54. Y Ogura DK Bonen N Inohara DL Nicolae FF Chen R Ramos 2001 A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease Nature 411 603-6 11385577 10.1038/35079114 1:CAS:528:DC%2BD3MXksVShur8%3D
55. N Inohara Y Ogura A Fontalba O Gutierrez F Pons J Crespo 2003 Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease J Biol Chem 278 5509-12 12514169 10.1074/jbc.C200673200 1:CAS:528:DC%2BD3sXht1aqsro%3D
56. S Maeda LC Hsu H Liu LA Bankston M Iimura MF Kagnoff 2005 Nod2 mutation in Crohn's disease potentiates NF-kappaB activity and IL-1beta processing Science 307 734-8 15692052 10.1126/science.1103685 1:CAS:528:DC%2BD2MXpt1WqtA%3D%3D
57. SE Girardin JP Hugot PJ Sansonetti 2003 Lessons from Nod2 studies: towards a link between Crohn's disease and bacterial sensing Trends Immunol 24 652-8 14644139 10.1016/j.it.2003.10.007 1:CAS:528:DC%2BD3sXptlyhsr4%3D
58. T Watanabe A Kitani PJ Murray W Strober 2004 NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses Nat Immunol 5 800-8 15220916 10.1038/ni1092 1:CAS:528:DC%2BD2cXmtVCgtL8%3D
59. J Bilsborough JL Viney 2004 Gastrointestinal dendritic cells play a role in immunity, tolerance, and disease Gastroenterology 127 300-9 15236195 10.1053/j.gastro.2004.01.028 1:CAS:528:DC%2BD2cXmsVShsLw%3D
60. JH Niess S Brand X Gu L Landsman S Jung BA McCormick 2005 CX3CR1-mediated dendritic cell access to the intestinal lumen and bacterial clearance Science 307 254-8 15653504 10.1126/science.1102901 1:CAS:528:DC%2BD2MXisVKltQ%3D%3D
61. TC Savidge PG Newman WH Pan MQ Weng HN Shi BA McCormick 2006 Lipopolysaccharide-induced human enterocyte tolerance to cytokine-mediated interleukin-8 production may occur independently of TLR-4/MD-2 signaling Pediatr Res 59 89-95 16326999 10.1203/ 01.pdr.0000195101.74184.e3 1:CAS:528:DC%2BD2MXhtlert7zF
62. P Tyrer AR Foxwell AW Cripps MA Apicella JM Kyd 2006 Microbial pattern recognition receptors mediate M-cell uptake of a gram-negative bacterium Infect Immun 74 625-31 16369019 10.1128/IAI.74.1.625-631.2006 1:CAS:528:DC%2BD28XitlKrug%3D%3D
63. JR Korzenik BK Dieckgraefe 2000 Is Crohn's disease an immunodeficiency? A hypothesis suggesting possible early events in the pathogenesis of Crohn's disease Dig Dis Sci 45 1121-9 10877227 10.1023/A:1005541700805 1:STN:280:DC%2BD3czjtlOhsg%3D%3D
64. JR Korzenik BK Dieckgraefe 2005 An open-labelled study of granulocyte colony-stimulating factor in the treatment of active Crohn's disease Aliment Pharmacol Ther 21 391-400 15709989 10.1111/ j.1365-2036.2005.02287.x 1:CAS:528:DC%2BD2MXisFCrsbo%3D
65. BK Dieckgraefe JR Korzenik 2002 Treatment of active Crohn's disease with recombinant human granulocyte-macrophage colony-stimulating factor [see comment] Lancet 360 1478-80 12433518 10.1016/S0140-6736(02)11437-1
66. JR Korzenik BK Dieckgraefe JF Valentine DF Hausman MJ Gilbert 2005 Sargramostim in Crohn's Disease Study G. Sargramostim for active Crohn's disease N Engl J Med 352 2193-201 15917384 10.1056/NEJMoa041109 1:CAS:528:DC%2BD2MXksFOlsro%3D
67. http://www.schering.de/scripts/en/50_media/2006/pi/Q3/ 060731_Leukine.php?n=mep accessed on 10 December 2006
68. TR Mosmann S Sad 1996 The expanding universe of T-cell subsets: Th1, Th2 and more Immunol Today 17 138-46 8820272 10.1016/0167-5699(96)80606-2 1:CAS:528:DyaK28XhsVensLo%3D
69. IJ Fuss M Neurath M Boirivant JS Klein C de la Motte SA Strong 1996 Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5 J Immunol 157 1261-70 8757634 1:CAS:528:DyaK28XksFKhtLY%3D
70. B Derkx J Taminiau S Radema A Stronkhorst C Wortel G Tytgat 1993 Tumour-necrosis-factor antibody treatment in Crohn's disease Lancet 342 173-4 8101267 10.1016/0140-6736(93)91375-V 1:STN:280:ByyA38zmtlE%3D
71. HM van Dullemen SJ Van Deventer DW Hommes HA Bijl J Jansen GN Tytgat 1995 Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2) Gastroenterology 109 129-35 7797011 10.1016/0016-5085(95)90277-5 1:STN:280:ByqA3MjltlQ%3D
72. SR Targan SB Hanauer SJ van Deventer L Mayer DH Present T Braakman 1997 A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group N Engl J Med 337 1029-35 9321530 10.1056/NEJM199710093371502 1:CAS:528:DyaK2sXmvVKjsrs%3D
73. SB Hanauer BG Feagan GR Lichtenstein LF Mayer S Schreiber JF Colombel 2002 Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial Lancet 359 1541-9 12047962 10.1016/S0140-6736(02)08512-4 1:CAS:528:DC%2BD38Xkt1Gru70%3D
74. BE Sands FH Anderson CN Bernstein WY Chey BG Feagan RN Fedorak 2004 Infliximab maintenance therapy for fistulizing Crohn's disease N Engl J Med 350 876-85 14985485 10.1056/NEJMoa030815 1:CAS:528:DC%2BD2cXhsFyitLo%3D
75. SB Hanauer WJ Sandborn P Rutgeerts RN Fedorak M Lukas D MacIntosh 2006 Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: The CLASSIC-I trial Gastroenterology 130 323-33 16472588 10.1053/j.gastro.2005.11.030 1:CAS:528:DC%2BD28Xit1alu7o%3D quiz 591
76. S Schreiber P Rutgeerts RN Fedorak M Khaliq-Kareemi MA Kamm M Boivin 2005 A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease Gastroenterology 129 807-18 16143120 10.1053/j.gastro.2005.06.064 1:CAS:528:DC%2BD2MXhtV2isrrK
77. JF Colombel WJ Sandborn P Rutgeerts R Enns SB Hanauer R Panaccione 2006 Adalimumab induces and maintains clinical response and remission in patients with active Crohn's disease: Results of the CHARM trial Gastroenterology 131 95010.1053/j.gastro.2006.06.098
78. WJ Sandborn BG Feagan S Stoinov PJ Honiball P Rutgeerts JA McColm 2006 Certolizumab pegol administered subcutaneously is effective and well tolerated in patients with active Crohn's disease: Results from a 26-week, placebo-controlled phase iii study (PRECiSE 1) Gastroenterology 130 A107
79. CA Siegel C Hur JR Korzenik GS Gazelle BE Sands 2006 Risks and benefits of infliximab for the treatment of Crohn's disease Clin Gastroenterol Hepatol 4 1017-24 16843733 10.1016/j.cgh.2006.05.020 1:CAS:528:DC%2BD28XptFWmtrc%3D quiz 976
80. JF Colombel EV Loftus Jr WJ Tremaine LJ Egan WS Harmsen CD Schleck 2004 The safety profile of infliximab in patients with Crohn's disease: The Mayo clinic experience in 500 patients Gastroenterology 126 19-31 14699483 10.1053/j.gastro.2003.10.047 1:CAS:528:DC%2BD2cXhtFGnt7c%3D
81. S Schreiber RN Fedorak OH Nielsen G Wild CN Williams S Nikolaus 2000 Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group Gastroenterology 119 1461-72 11113067 10.1053/gast.2000.20196 1:CAS:528:DC%2BD3MXhtlKgtA%3D%3D
82. G Van Assche WJ Sandborn BG Feagan BA Salzberg D Silvers PS Monroe 2006 Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: A randomised, double blind, placebo controlled, dose ranging trial Gut 55 1568-74 16603634 10.1136/gut.2005.089854 1:CAS:528:DC%2BD28Xht1GkurvI
83. PJ Mannon IJ Fuss L Mayer CO Elson WJ Sandborn D Present 2004 Anti-interleukin-12 antibody for active Crohn's disease N Engl J Med 351 2069-79 15537905 10.1056/NEJMoa033402 1:CAS:528:DC%2BD2cXpslegs74%3D
84. RH Duerr KD Taylor SR Brant JD Rioux MS Silverberg MJ Daly 2006 A Genome-Wide Association Study Identifies IL23R as an Inflammatory Bowel Disease Gene Science 314 1461-3 17068223 10.1126/science.1135245 1:CAS:528:DC%2BD28Xht1CntrjF
85. Springer TA. Adhesion receptors of the immune system. Nature 1990;346:425-34
86. C Berlin EL Berg MJ Briskin DP Andrew PJ Kilshaw B Holzmann 1993 Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1 Cell 74 185-95 7687523 10.1016/0092-8674(93)90305-A 1:CAS:528:DyaK3sXltlOhtb0%3D
87. S Ghosh E Goldin FH Gordon HA Malchow J Rask-Madsen P Rutgeerts 2003 Natalizumab for active Crohn's disease N Engl J Med 348 24-32 12510039 10.1056/NEJMoa020732 1:CAS:528:DC%2BD3sXhsVSltg%3D%3D
88. WJ Sandborn JF Colombel R Enns BG Feagan SB Hanauer IC Lawrance 2005 Natalizumab induction and maintenance therapy for Crohn's disease N Engl J Med 353 1912-25 16267322 10.1056/NEJMoa043335 1:CAS:528:DC%2BD2MXhtF2rsbzF
89. S Targan B Feagan R Fedorak B Lashner R Panacionne D Present 2006 Natalizumab induces sustained response and remission in patients with active Crohn's disease: Results from the Encore trial Gastroenterology 130 A108
90. G Van Assche M Van Ranst R Sciot B Dubois S Vermeire M Noman 2005 Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease N Engl J Med 353 362-8 15947080 10.1056/NEJMoa051586 1:CAS:528:DC%2BD2MXms1Kntrk%3D
91. BG Feagan GR Greenberg G Wild RN Fedorak P Pare JW McDonald 2005 Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin N Engl J Med 352 2499-507 15958805 10.1056/ NEJMoa042982 1:CAS:528:DC%2BD2MXltlaksb4%3D
92. BG Feagan 2003 MLN-02 Crohn's disease Gastroenterology 124 A2510.1016/ S0016-5085(03)80125-7
93. WE Paul RA Seder 1994 Lymphocyte responses and cytokines Cell 76 241-51 7904900 10.1016/0092-8674(94)90332-8 1:CAS:528:DyaK2cXhs1Srtr8%3D
94. RA Seder RN Germain PS Linsley WE Paul 1994 CD28-mediated costimulation of interleukin 2 (IL-2) production plays a critical role in T cell priming for IL-4 and interferon gamma production J Exp Med 179 299-304 8270872 10.1084/jem.179.1.299 1:CAS:528:DyaK2cXnsFWlsw%3D%3D
95. S Katz 2005 Update in medical therapy of ulcerative colitis: Newer concepts and therapies [erratum appears in J Clin Gastroenterol 2005;39:843 J Clin Gastroenterol 39 557-69 16000921 10.1097/ 01.mcg.0000170735.43887.3a
96. MC Genovese JC Becker M Schiff M Luggen Y Sherrer J Kremer 2005 Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition N Engl J Med 353 1114-23 16162882 10.1056/NEJMoa050524 1:CAS:528:DC%2BD2MXhtVWhsbnI
97. H Groux A O'Garra M Bigler M Rouleau S Antonenko JE de Vries 1997 A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis Nature 389 737-42 9338786 10.1038/39614 1:CAS:528:DyaK2sXmvVSgtb0%3D
98. HL Weiner 2001 Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells Immunol Rev 182 207-14 11722636 10.1034/j.1600-065X.2001.1820117.x 1:CAS:528:DC%2BD3MXpt1eisbo%3D
99. D Dieckmann CH Bruett H Ploettner MB Lutz G Schuler 2002 Human CD4(+)CD25(+) regulatory, contact-dependent T cells induce interleukin 10-producing, contact-independent type 1-like regulatory T cells J Exp Med 196 247-53 12119349 10.1084/jem.20020642 1:CAS:528:DC%2BD38XlsV2ms7g%3D
100. C Van Montfrans E Hooijberg MS Rodriguez Pena EC De Jong H Spits AA Te Velde 2002 Generation of regulatory gut-homing human T lymphocytes using ex vivo interleukin 10 gene transfer Gastroenterology 123 1877-88 12454845 10.1053/gast.2002.37066 1:CAS:528:DC%2BD38Xps1yktbo%3D
101. Hurles M. Are 100 000 "SNPs" useless? Science 2002;298:1509; author reply 1509